CytomX Therapeutics, Inc. (CTMX) Free cash flow
- Free cash flow · 12 months (USD): Value $-82.48M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -450.65%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-82.48M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-82.41M − $74.00K ≈ $-82.48M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -450.65% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-82.48M ÷ $18.30M × 100 ≈ -450.65% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-82.41M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 1.03× | Operating cash flow / net income. Period ending 2026-06-30. $-82.41M ÷ $-79.65M ≈ 1.03× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -82.41M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 74.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -82.48M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 18.30M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -79.65M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-82.48M | (m) | $-82.41M | $74.00K | (m) | $18.30M | (m) | $-79.65M | (m) | (m) | -450.65% | 1.03× |
| 2026-03-31 | $-80.19M | (m) | $-80.09M | $101.00K | (m) | $35.54M | (m) | $-59.14M | (m) | (m) | -225.63% | 1.35× |
| 2025-12-31 | $-75.81M | (m) | $-75.59M | $220.00K | (m) | $76.20M | (m) | $-17.37M | (m) | (m) | -99.48% | 4.35× |
| 2025-09-30 | $-72.35M | (m) | $-72.25M | $99.00K | (m) | $113.63M | (m) | $28.02M | (m) | (m) | -63.67% | -2.58× |
| 2025-06-30 | $-77.68M | (m) | $-77.43M | $245.00K | (m) | $141.10M | (m) | $47.98M | (m) | (m) | -55.05% | -1.61× |
| 2025-03-31 | $-81.54M | (m) | $-81.23M | $314.00K | (m) | $147.56M | (m) | $41.60M | (m) | (m) | -55.26% | -1.95× |
| 2024-12-31 | $-86.54M | (m) | $-86.23M | $310.00K | (m) | $138.10M | (m) | $31.87M | (m) | (m) | -62.66% | -2.71× |
| 2024-09-30 | $-88.78M | (m) | $-88.29M | $496.00K | (m) | $126.62M | (m) | $13.83M | (m) | (m) | -70.12% | -6.38× |
| 2024-06-30 | $-86.29M | (m) | $-85.80M | $486.00K | (m) | $119.57M | (m) | $11.09M | (m) | (m) | -72.16% | -7.74× |
| 2024-03-31 | $-92.34M | (m) | $-91.43M | $907.00K | (m) | $119.18M | (m) | $16.53M | (m) | (m) | -77.48% | -5.53× |
| 2023-12-31 | $-56.88M | (m) | $-56.03M | $840.00K | (m) | $101.21M | (m) | $-569.00K | (m) | (m) | -56.19% | 98.48× |
| 2023-09-30 | $-36.22M | (m) | $-35.47M | $756.00K | (m) | $94.73M | (m) | $-10.18M | (m) | (m) | -38.24% | 3.48× |
| 2023-06-30 | $-52.22M | (m) | $-51.07M | $1.16M | (m) | $79.49M | (m) | $-42.24M | (m) | (m) | -65.70% | 1.21× |
| 2023-03-31 | $-61.18M | (m) | $-60.13M | $1.05M | (m) | $67.62M | (m) | $-70.65M | (m) | (m) | -90.47% | 0.85× |
| 2022-12-31 | $-112.53M | (m) | $-110.79M | $1.74M | (m) | $53.16M | (m) | $-99.32M | (m) | (m) | -211.67% | 1.12× |
| 2022-09-30 | $-142.39M | (m) | $-140.59M | $1.80M | (m) | $71.94M | (m) | $-97.59M | (m) | (m) | -197.92% | 1.44× |
| 2022-06-30 | $-138.10M | (m) | $-136.44M | $1.66M | (m) | $72.62M | (m) | $-96.88M | (m) | (m) | -190.18% | 1.41× |
| 2022-03-31 | $-131.77M | (m) | $-130.40M | $1.36M | (m) | $70.74M | (m) | $-91.94M | (m) | (m) | -186.27% | 1.42× |
| 2021-12-31 | $-120.64M | (m) | $-119.03M | $1.61M | (m) | $69.57M | (m) | $-83.61M | (m) | (m) | -173.40% | 1.42× |
| 2021-09-30 | $-107.08M | (m) | $-105.27M | $1.81M | (m) | $66.22M | (m) | $-72.08M | (m) | (m) | -161.70% | 1.46× |
| 2021-06-30 | $-102.56M | (m) | $-100.24M | $2.32M | (m) | $66.42M | (m) | $-64.21M | (m) | (m) | -154.42% | 1.56× |
| 2021-03-31 | $22.81M | (m) | $25.06M | $2.24M | (m) | $66.74M | (m) | $-60.64M | (m) | (m) | 34.18% | -0.41× |
| 2020-12-31 | $2.95M | (m) | $5.26M | $2.31M | (m) | $100.36M | (m) | $-32.88M | (m) | (m) | 2.94% | -0.16× |
| 2020-09-30 | $-9.36M | (m) | $-6.79M | $2.57M | (m) | $92.27M | (m) | $-53.64M | (m) | (m) | -10.14% | 0.13× |
| 2020-06-30 | $-7.85M | (m) | $-5.43M | $2.42M | (m) | $85.19M | (m) | $-62.63M | (m) | (m) | -9.22% | 0.09× |
| 2020-03-31 | $-153.90M | (m) | $-151.19M | $2.71M | (m) | $77.60M | (m) | $-75.91M | (m) | (m) | -198.33% | 1.99× |
| 2019-12-31 | $-143.98M | (m) | $-140.48M | $3.50M | (m) | $57.49M | (m) | $-102.24M | (m) | (m) | -250.44% | 1.37× |
| 2019-09-30 | $-143.66M | (m) | $-139.74M | $3.91M | (m) | $60.68M | (m) | $-99.02M | (m) | (m) | -236.74% | 1.41× |
| 2019-06-30 | $-126.31M | (m) | $-121.97M | $4.33M | (m) | $62.48M | (m) | $-98.75M | (m) | (m) | -202.17% | 1.24× |
| 2019-03-31 | $-104.81M | (m) | $-99.94M | $4.87M | (m) | $74.80M | (m) | $-83.23M | (m) | (m) | -140.11% | 1.20× |
| 2018-12-31 | $-79.31M | (m) | $-75.52M | $3.79M | (m) | $59.50M | (m) | $-84.60M | (m) | (m) | -133.29% | 0.89× |
| 2018-09-30 | $-27.68M | (m) | $-24.78M | $2.90M | (m) | $75.10M | (m) | $-51.75M | (m) | (m) | -36.86% | 0.48× |
| 2018-06-30 | $-26.87M | (m) | $-24.96M | $1.91M | (m) | $86.74M | (m) | $-38.57M | (m) | (m) | -30.98% | 0.65× |
| 2018-03-31 | $173.48M | (m) | $174.85M | $1.37M | (m) | $74.15M | (m) | $-50.34M | (m) | (m) | 233.95% | -3.47× |
| 2017-12-31 | $168.81M | (m) | $170.37M | $1.56M | (m) | $71.62M | (m) | $-43.10M | (m) | (m) | 235.70% | -3.95× |
| 2017-09-30 | $148.38M | (m) | $150.31M | $1.93M | (m) | $50.82M | (m) | $-57.75M | (m) | (m) | 291.96% | -2.60× |
| 2017-06-30 | $139.13M | (m) | $141.86M | $2.73M | (m) | $30.13M | (m) | $-62.17M | (m) | (m) | 461.75% | -2.28× |
| 2017-03-31 | $-18.37M | (m) | $-15.58M | $2.79M | (m) | $24.47M | (m) | $-51.13M | (m) | (m) | -75.07% | 0.30× |
| 2016-12-31 | $-4.21M | (m) | $-2.03M | $2.18M | (m) | $15.04M | (m) | $-58.90M | (m) | (m) | -27.97% | 0.03× |
| 2016-09-30 | $-13.89M | (m) | $-12.14M | $1.76M | (m) | $10.76M | (m) | $-56.35M | (m) | (m) | -129.13% | 0.22× |
| 2016-06-30 | $-6.98M | (m) | $-5.72M | $1.26M | (m) | $9.24M | (m) | $-53.56M | (m) | (m) | -75.48% | 0.11× |
| 2016-03-31 | $-29.25M | (m) | $-27.59M | $1.67M | (m) | $8.19M | (m) | $-45.19M | (m) | (m) | -357.04% | 0.61× |
| 2015-12-31 | $-29.01M | (m) | $-27.41M | $1.59M | (m) | $7.71M | (m) | $-35.37M | (m) | (m) | -376.15% | 0.78× |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | $7.56M | (m) | $-20.39M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | $6.18M | (m) | $-19.52M | (m) | (m) | (m) | (m) |
| 2014-12-31 | $30.14M | (m) | $31.80M | $1.66M | (m) | $5.08M | (m) | $-30.31M | (m) | (m) | 593.64% | -1.05× |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-8.74M | (m) | $-8.01M | $732.00K | (m) | $888.00K | (m) | $-15.14M | (m) | (m) | -984.23% | 0.53× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |